tailieunhanh - Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)

Lenalidomide has been approved for the treatment of lower-risk myelodysplastic syndrome (MDS) with 5q deletion (del(5q)). We present for the first time a retrospective analysis of low-risk MDS with isolated del5q treated with lenalidomide, outside the clinical trials. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN